Grifols SA Files 20-F for FY2024
Ticker: GIKLY · Form: 20-F · Filed: Apr 11, 2025 · CIK: 1438569
| Field | Detail |
|---|---|
| Company | Grifols SA (GIKLY) |
| Form Type | 20-F |
| Filed Date | Apr 11, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 20-F, financials, subsidiaries
TL;DR
Grifols 20-F is in: FY24 financials, subsidiaries, and stock info detailed.
AI Summary
Grifols SA filed its 20-F for the fiscal year ending December 31, 2024. The filing details financial performance and business operations, including information on restricted stock units and pension plans. Key subsidiaries and brand names like Progenika Biopharma SA and Biotest AG are mentioned, along with intangible assets related to Access Biologicals LLC.
Why It Matters
This filing provides investors with a comprehensive overview of Grifols SA's financial health and strategic positioning for the past fiscal year, impacting investment decisions.
Risk Assessment
Risk Level: medium — The filing contains detailed financial information and disclosures about subsidiaries, which are crucial for assessing the company's overall risk profile.
Key Numbers
- 457,000,000 — Equity Settled Share Based Payment Plan (Related to IFRS Restricted Stock Units)
- 156,291,1000 — Pension Defined Benefit Plans (Financial data for 2024)
Key Players & Entities
- Grifols SA (company) — Filer of the 20-F
- Progenika Biopharma SA (company) — Subsidiary/Brand Name
- Biotest AG (company) — Subsidiary/Brand Name
- Access Biologicals LLC (company) — Subsidiary with customer-related intangible assets
- 2024-12-31 (date) — Fiscal year end date
FAQ
What is the total value of Grifols SA's equity settled share-based payment plan for the fiscal year 2024?
The filing indicates a value of 457,000,000 related to the Equity Settled Share Based Payment Plan for the period ending December 31, 2024.
Which subsidiaries or brand names are specifically mentioned in the context of intangible assets for 2024?
Progenika Biopharma SA (Brand Names), Biotest AG (Brand Names), and Access Biologicals LLC (Customer-related Intangible Assets) are mentioned for the period ending December 31, 2024.
What are the reported figures for Grifols SA's pension defined benefit plans for the fiscal year 2024?
The filing provides financial data for Pension Defined Benefit Plans for the period ending December 31, 2024, with a value of 156,291,1000.
When were the intangible assets related to Biotest AG, specifically In Process Research and Development and Distribution Agreements, first noted?
These intangible assets related to Biotest AG were noted on April 25, 2022.
What is the filing period for the Grifols SA 20-F?
The Conformed Period of Report is December 31, 2024.
Filing Details
This Form 20-F (Form 20-F) was filed with the SEC on April 11, 2025 regarding Grifols SA (GIKLY).